RAPT - NASDAQ
RAPT Therapeutics, Inc.
$58.01
+0.0000%RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotRAPT Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
RAPT Therapeutics, Inc. Balance Sheet
RAPT • NASDAQ
| RAPT Therapeutics, Inc. Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
169.7M | 47.5M | 38.9M | 24M | 24.9M | 77.4M | 63.8M | 47.5M | |
61.3M | 111.4M | 210.1M | 165.6M | 86.6M | 0.0 | 0.0 | 0.0 | |
231.1M | 158.9M | 249.1M | 189.7M | 111.5M | 77.4M | 63.8M | 47.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.1M | 1.3M | 725K | |
4.2M | 2.9M | 3.6M | 3.3M | 4.1M | 0.0 | 0.0 | 0.0 | |
235.2M | 161.8M | 252.7M | 193M | 115.6M | 80.5M | 65.1M | 48.2M | |
NON-CURRENT ASSETS | ||||||||
4.7M | 7.7M | 9.5M | 2.7M | 3M | 3.7M | 4.2M | 1.9M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 598K | 605K | |
389K | 3.9M | 4M | 2.9M | 389K | 389K | -209K | -369K | |
5.1M | 11.5M | 13.5M | 5.7M | 3.4M | 4.1M | 4.5M | 2.1M | |
1K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
240.3M | 173.3M | 266.2M | 198.6M | 119M | 84.6M | 69.6M | 50.4M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
36.3M | 5.2M | 3.4M | 2M | 2.4M | 1.1M | 1.8M | 1.1M | |
1.3M | 5.2M | 3.4M | 2M | 2.4M | 1.1M | 1.8M | 1.1M | |
35M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.9M | 6.3M | 4M | 3.7M | 3M | 1.9M | 2.3M | 1.5M | |
2.4M | 2.4M | 2.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 1M | 4.1M | 4M | 0.0 | 0.0 | |
6.8M | 7.9M | 4.7M | 2.9M | 2.3M | 2.3M | 586K | 650K | |
48.4M | 21.8M | 14.2M | 9.6M | 11.7M | 9.3M | 4.6M | 3.2M | |
NON-CURRENT LIABILITIES | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 108.6M | |
0.0 | 0.0 | 0.0 | 511K | 863K | 0.0 | 969K | 905K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -162.1M | -108.6M | |
0.0 | 0.0 | 0.0 | 2.2M | 2.2M | 2.2M | 969K | 905K | |
2.1M | 4.5M | 6.8M | 2.7M | 3M | 2.2M | 969K | 109.5M | |
4.5M | 6.9M | 9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
50.4M | 26.3M | 21M | 12.3M | 14.8M | 11.5M | 5.6M | 112.8M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 161.1M | 108.6M | |
13K | 3K | 3K | 3K | 2K | 2K | 2K | 1K | |
804.4M | 631.6M | 613.1M | 470.6M | 319.2M | 235M | 22.4M | 21M | |
-614.5M | -484.7M | -367.9M | -284M | -214.8M | -162M | -119M | -82.8M | |
50K | 103K | -26K | -206K | -177K | 20K | -4K | -3.8M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 160.5M | 3.8M | |
189.9M | 147M | 245.2M | 186.4M | 104.2M | 73.1M | 64M | -62.4M | |
189.9M | 147M | 245.2M | 186.4M | 104.2M | 73.1M | 64M | -62.4M | |
SUMMARY | ||||||||
240.3M | 173.3M | 266.2M | 198.6M | 119M | 84.6M | 69.6M | 50.4M | |
61.3M | 111.4M | 210.1M | 165.6M | 86.6M | 0.0 | 598K | 605K | |
4.5M | 6.9M | 9M | 0.0 | 0.0 | 0.0 | 161.1M | 108.6M | |
-165.2M | -40.6M | -30M | -24M | -24.9M | -77.4M | 97.3M | 61.1M | |
16,537,490 | 16,537,490 | 16,537,490 | 16,537,490 | 16,537,490 | 16,537,490 | 16,537,490 | 16,537,490 |
SEC Filings
RAPT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 20, 2026 | January 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 14, 2026 | January 14, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 28, 2025 | November 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 23, 2025 | October 21, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 20, 2025 | October 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your RAPT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.